| Dr Robert D Hillstead, OD | |
|
840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 | |
| (702) 346-1994 | |
| (702) 346-2056 |
| Full Name | Dr Robert D Hillstead |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 34 Years |
| Location | 840 Pinnacle Ct Ste 10a, Mesquite, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497811467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 261 (Nevada) | Primary |
| Provider Name | Robert D. Hillstead, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073702841 PECOS PAC ID: 6002906369 Enrollment ID: O20071226000490 |
News Archive
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials, which will be a welcome event for disease sufferers who currently have few treatment options.
The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
According to the American Cancer Society, an estimated 82,770 Americans will be diagnosed this year with skin cancer, including melanoma. When left untreated, melanoma is the most dangerous and aggressive form of skin cancer, accounting for more than 9,000 of the 12,000-plus skin cancer deaths each year.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert D Hillstead, OD 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 Ph: (702) 346-1994 | Dr Robert D Hillstead, OD 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 Ph: (702) 346-1994 |
News Archive
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials, which will be a welcome event for disease sufferers who currently have few treatment options.
The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution.
A team of researchers from the National University of Singapore has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol-generating procedures on COVID-19 patients.
According to the American Cancer Society, an estimated 82,770 Americans will be diagnosed this year with skin cancer, including melanoma. When left untreated, melanoma is the most dangerous and aggressive form of skin cancer, accounting for more than 9,000 of the 12,000-plus skin cancer deaths each year.
› Verified 8 days ago
Dr. Scott Kirk Brotherson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 61 N Willow St, Suite 2, Mesquite, NV 89027 Phone: 702-346-3031 | |
Robert D. Hillstead, Inc Optometrist Medicare: Medicare Enrolled Practice Location: 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027 Phone: 702-346-1994 Fax: 702-346-2056 | |
Brett P Richardson Od Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 1120 W Pioneer Blvd, Mesquite, NV 89027 Phone: 360-991-9548 | |
Vision Consultants Optometrist Medicare: Not Enrolled in Medicare Practice Location: 272 W Pioneer Blvd, Mesquite, NV 89027 Phone: 775-375-8869 | |
Brett Richardson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1120 W Pioneer Blvd, Mesquite, NV 89027 Phone: 360-991-9548 | |
Scott K Brotherson O.d. Optometrist Medicare: Medicare Enrolled Practice Location: 61 N Willow St, Suite 2, Mesquite, NV 89027 Phone: 702-346-3031 Fax: 702-346-0920 |